Inhibitors of the mammalian target of rapamycin
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The mammalian target of rapamycin (mTOR) is a downstream protein kinase of the phosphatidylinositol 3'-kinase-Akt signalling pathway. As a result of its position within this pathway and its central role in controlling cellular growth, mTOR is viewed as an important target for anticancer therapeutics development. Currently, the mTOR inhibitor rapamycin (sirolimus, Wyeth) and its derivatives temsirolimus (CCI-779, Wyeth), everolimus (RAD-001, Novartis Pharma AG) and AP-23573 (Ariad Pharmaceuticals) are being evaluated in cancer clinical trials. Preclinical studies suggest that sensitivity to mTOR inhibition may correlate with aberrant activation of the phosphatidylinositol 3'-kinase pathway and/or with aberrant expression of cell-cycle regulatory or antiapoptotic proteins. Clinical trial results show that mTOR inhibitors are generally well tolerated and may induce prolonged stable disease and even tumour regressions in a subset of patients. Questions remain regarding optimal dose, schedule, patient selection and combination strategies for this novel class of agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083 · cited 1×
“Following its phosphorylation, TSC2 destabilises, disrupting the formation of functional TSC1/2 complexes and removing their inhibitory effect on mTOR [10-12].”
BackgroundRheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911 · cited 1×
“Following its phosphorylation, TSC2 destabilises, disrupting the formation of functional TSC1/2 complexes and removing their inhibitory effect on mTOR [10-12].”
BackgroundLoewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886 · cited 1×
“mTOR functions in a complex with at least two other proteins: regulatory associated protein of mTOR (raptor) [19,20] and mammalian orthologue of LST8 (mLST8, also known as G-protein β-subunit-like protein [GβL]) [20,21].”
BackgroundBrugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 1×
“Drugs (2005) 14(3) functions in a protein complex that integrates signals from a variety of sources, including growth factors, energy stores and hypoxia, with the protein translation apparatus [4].”
BackgroundHudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186
Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes
Blommaart, E. F. C., Luiken, J. J. F. P., Blommaart, P. J. E., van Woerkom, G. M., & Meijer, A. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.5.2320 · Cited by 686 · cited 1×
“mTOR has been reported to regulate autophagy [29,30].”
BackgroundRheb fills a GAP between TSC and TOR
Manning, B. (2003) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.09.003 · Cited by 483 · cited 1×
“TSC2 acts as a GTPase-activating protein (GAP) toward the Ras-related small GTPase Rheb (Ras homologue enriched in brain) [15], a positive upstream regulator of mTOR.”
BackgroundRajasekhar, V. K., Viale, A., Socci, N. D., Wiedmann, M., Hu, X., & Holland, E. C. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00395-2 · Cited by 420 · cited 1×
“For example, signalling through Ras and Akt acts rapidly to increase the association of mRNA transcripts with polyribosomes, and, therefore, may immediately and broadly influence protein translation [40].”
BackgroundRhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis
Kwiatkowski, D. J. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.5.446 · Cited by 387 · cited 2×
“Drugs (2005) 14(3) 315 or through loss of TSC2 function through mutation, as occurs in TS patients, allows Rheb to activate mTOR and leads to the phosphorylation of the downstream mTOR targets [8].”
Background
Cited by
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
The tumor microenvironment and its contribution to tumor evolution toward metastasis
Lorusso, G., & Rüegg, C. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0530-8 · Cited by 531
Tabernero, J., Rojo, F., Calvo, E., Burris, H., Judson, I., Hazell, K., Martinelli, E., Cajal, S. R. Y., Jones, S., Vidal, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5482 · Cited by 474
Akt Signals through the Mammalian Target of Rapamycin Pathway to Regulate CNS Myelination
Narayanan, S. P., Flores, A. I., Wang, F., & Macklin, W. B. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0232-09.2009 · Cited by 325
Mitra, A. P., Datar, R. H., & Cote, R. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2073 · Cited by 284
Targeting signal transduction as a strategy to treat inflammatory diseases
O'Neill, L. A. J. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2070 · Cited by 283
Inhibition of mTOR Signaling in Parkinson’s Disease Prevents l -DOPA–Induced Dyskinesia
Santini, E., Heiman, M., Greengard, P., Valjent, E., & Fisone, G. (2009) · Science Signaling · doi:10.1126/scisignal.2000308 · Cited by 259
Chawla, S. P., Staddon, A. P., Baker, L. H., Schuetze, S. M., Tolcher, A. W., D'Amato, G. Z., Blay, J.-Y., Mita, M. M., Sankhala, K. K., Berk, L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6329 · Cited by 246
Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII)
Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2015) · Epilepsy Research · doi:10.1016/j.eplepsyres.2015.01.001 · Cited by 174
Ahmed, M., & Kundu, G. C. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-101 · Cited by 67
Metadata
- Authors
- Dancey, J. E.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2005-03
- Volume
- 14
- Issue
- 3
- Pages
- 313-328
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2163140784
- Cited by
- 95
- References
- 11
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.